Morgan Stanley analyst Vikram Purohit resumed coverage of Genmab with an Equal Weight rating and $31 price target. The next key event for the shares is the HexaBody-CD38 data and Johnson & Johnson’s opt-in decision, which may be available by the end of 2024 or early 2025, the analyst tells investors in a research note. The firm says visibility into the opt-in is limited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Hookipa Pharma appoints O’Neill as non-executive chair of board
- Genmab price target lowered to DKK 2,500 from DKK 2,750 at Deutsche Bank
- Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- Genmab’s TEPKINLY Gains EU Approval for Lymphoma
- Genmab downgraded to Neutral from Overweight at JPMorgan